Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: MCHR1 protein antagonists - AMRI

Drug Profile

Research programme: MCHR1 protein antagonists - AMRI

Alternative Names: AMR-MCH-1; AMR-MCH-14; AMR-MCH-18; AMR-MCH-2

Latest Information Update: 28 Apr 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AMRI
  • Class Dihydropyridines; Indazoles; Small molecules
  • Mechanism of Action MCHR1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Obesity

Highest Development Phases

  • Discontinued Obesity

Most Recent Events

  • 28 Apr 2016 The MCHR1 protein antagonists programme is available for licensing as of 28 Apr 2016. http://www.amriglobal.com/
  • 08 Nov 2011 Discontinued - Preclinical for Obesity in USA (PO)
  • 20 Aug 2009 Pharmacodynamics data from a preclinical trial in Obesity presented at the 238th American Chemical Society National Meeting (ACS-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top